High Stakes, New Strategies: Tackling Severe Alcohol-Associated Hepatitis

Nov 10 2025
Convention Center: Ballroom B, Level 3
2:00 PM - 3:30 PM

World Class Speakers

Maddie Kubiliun, MD, MPH
Abstract Presenter

Maddie Kubiliun, MD, MPH

UT Southwestern
Helena Cortez-Pinto, MD, PhD, FAASLD
Abstract Presenter

Helena Cortez-Pinto, MD, PhD, FAASLD

Faculdade de Medicina, Universidade de Lisboa
Winston Dunn, MD, FAASLD
Abstract Presenter

Winston Dunn, MD, FAASLD

University of Kansas Medical Center
Helena Cortez-Pinto, MD, PhD, FAASLD
Moderator

Helena Cortez-Pinto, MD, PhD, FAASLD

Faculdade de Medicina, Universidade de Lisboa
Winston Dunn, MD, FAASLD
Moderator

Winston Dunn, MD, FAASLD

University of Kansas Medical Center

Description

In this session, presenters will explore emerging research on alcohol-associated liver disease (ALD), with a focus on severe alcohol-associated hepatitis (SAH). The session will highlight long-term outcomes following hospitalization and early liver transplantation for SAH, as well as introduce a novel therapeutic approach to its treatment. Additionally, it will examine a newly identified genetic risk modifier for ALD and investigate the potential influence of cannabis use on disease risk. Together, these abstracts aim to deepen understanding of disease mechanisms, treatment strategies, and risk factors in ALD.

Journey Maps

Presentations

2:00 PM - 2:15 PM
Aug 06 2026
Convention Center - Ballroom B, Level 3

Combination of Rifaximin, Plasma Exchange, and Granulocyte Colony Stimulating Factor with Standard Medical Therapy versus Standard Medical Therapy Alone in Severe Alcohol-associated Hepatitis: Results from the GRACE-AH Randomized Controlled

Maddie Kubiliun, MD, MPH , Abstract Presenter
Hepatitis
2:15 PM - 2:30 PM
Aug 06 2026
Convention Center - Ballroom B, Level 3

AIF-1 Genetic Upregulation is a Risk Factor for Alcohol-Associated Liver Disease Progression

Helena Cortez-Pinto, MD, PhD, FAASLD , Abstract Presenter
Hepatitis
2:30 PM - 2:45 PM
Aug 06 2026
Convention Center - Ballroom B, Level 3

Long-term outcomes following hospitalization for acute alcohol-associated hepatitis

Winston Dunn, MD, FAASLD , Abstract Presenter
Hepatitis
2:45 PM - 3:00 PM
Aug 06 2026
Convention Center - Ballroom B, Level 3

Reverse Transcriptase Inhibitors Are Associated with Reduced Liver-Related Complications in AUD: Establishing a Pathogenic Role of Endogenous Retroviruses in AH and ALD

Maddie Kubiliun, MD, MPH , Abstract Presenter
Hepatitis
3:00 PM - 3:15 PM
Aug 06 2026
Convention Center - Ballroom B, Level 3

Ten-year Post-Transplant Survival Outcomes after Early Liver Transplant for Severe Alcohol-Associated Hepatitis: An ACCELERATE-AH Study

Helena Cortez-Pinto, MD, PhD, FAASLD , Abstract Presenter
Hepatitis
3:15 PM - 3:30 PM
Aug 06 2026
Convention Center - Ballroom B, Level 3

The Impact of Cannabinoids on The Risk of Alcohol-Associated Liver Disease

Winston Dunn, MD, FAASLD , Abstract Presenter
Hepatitis

Objectives

  • Describe long-term outcomes following hospitalization and early liver transplant for severe alcohol-associated hepatitis
  • Discuss the potential for cannabis use as a risk modifier in ALD
  • Describe a novel genetic risk modifier for ALD